These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31924714)

  • 41. Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries.
    Sticherling C; Arendacka B; Svendsen JH; Wijers S; Friede T; Stockinger J; Dommasch M; Merkely B; Willems R; Lubinski A; Scharfe M; Braunschweig F; Svetlosak M; Zürn CS; Huikuri H; Flevari P; Lund-Andersen C; Schaer BA; Tuinenburg AE; Bergau L; Schmidt G; Szeplaki G; Vandenberk B; Kowalczyk E; Eick C; Juntilla J; Conen D; Zabel M;
    Europace; 2018 Jun; 20(6):963-970. PubMed ID: 29016784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Consideration of patient age and life expectancy in implantable cardioverter-defibrillator referral.
    Dewland TA; Hsu JC; Castellanos JM; Smith LM; Marcus GM
    Am Heart J; 2013 Jul; 166(1):164-70. PubMed ID: 23816036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Complications Associated With Implantable Cardioverter Defibrillators in Adults With Congenital Heart Disease or Left Ventricular Noncompaction Cardiomyopathy (From the NCDR
    Gleva MJ; Wang Y; Curtis JP; Berul CI; Huddleston CB; Poole JE
    Am J Cardiol; 2017 Nov; 120(10):1891-1898. PubMed ID: 28917495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-life outcome of implantable cardioverter-defibrillator and cardiac resynchronization defibrillator replacement/upgrade in a contemporary population: observations from the multicentre DECODE registry.
    Biffi M; Ammendola E; Menardi E; Parisi Q; Narducci ML; De Filippo P; Manzo M; Stabile G; Potenza DR; Zanon F; Quartieri F; Rillo M; Saporito D; Zacà V; Berisso MZ; Bertini M; Tumietto F; Malacrida M; Diemberger I
    Europace; 2019 Oct; 21(10):1527-1536. PubMed ID: 31209482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement.
    Heidenreich PA; Tsai V; Curtis J; Wang Y; Turakhia MP; Masoudi FA; Varosy PD; Goldstein MK
    Am Heart J; 2015 Aug; 170(2):281-289.e2. PubMed ID: 26299225
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database.
    MacFadden DR; Crystal E; Krahn AD; Mangat I; Healey JS; Dorian P; Birnie D; Simpson CS; Khaykin Y; Pinter A; Nanthakumar K; Calzavara AJ; Austin PC; Tu JV; Lee DS
    Ann Intern Med; 2012 Feb; 156(3):195-203. PubMed ID: 22312139
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up of implantable cardioverter-defibrillators in adult congenital heart disease patients: indications and outcomes.
    Santharam S; Hudsmith L; Thorne S; Clift P; Marshall H; De Bono J
    Europace; 2017 Mar; 19(3):407-413. PubMed ID: 27234868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the Charlson comorbidity index to predict early mortality in implantable cardioverter defibrillator patients.
    Bhavnani SP; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Ann Noninvasive Electrocardiol; 2013 Jul; 18(4):379-88. PubMed ID: 23879278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
    Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of Implantable Cardioverter Defibrillator Therapy and Mortality in Primary and Secondary Prevention of Sudden Cardiac Death.
    Konstantino Y; Shafat T; Novack V; Novack L; Amit G
    Isr Med Assoc J; 2015 Dec; 17(12):760-3. PubMed ID: 26897978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
    Pun PH; Hellkamp AS; Sanders GD; Middleton JP; Hammill SC; Al-Khalidi HR; Curtis LH; Fonarow GC; Al-Khatib SM
    Nephrol Dial Transplant; 2015 May; 30(5):829-35. PubMed ID: 25404241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Automated electrocardiographic quantification of myocardial scar in patients undergoing primary prevention implantable cardioverter-defibrillator implantation: Association with mortality and subsequent appropriate and inappropriate therapies.
    Reichlin T; Asatryan B; Vos MA; Willems R; Huikuri HV; Junttila MJ; Schlögl SC; Hnatkova K; Schaer BA; Malik M; Zabel M; Sticherling C;
    Heart Rhythm; 2020 Oct; 17(10):1664-1671. PubMed ID: 32428669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of appropriate implantable cardioverter-defibrillator therapy and mortality after implantable cardioverter-defibrillator generator replacement: results from a real-world nationwide cohort.
    Ruwald MH; Ruwald AC; Johansen JB; Gislason G; Nielsen JC; Philbert B; Riahi S; Vinther M; Lindhardt TB
    Europace; 2019 Aug; 21(8):1211-1219. PubMed ID: 31329849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term follow-up of adult patients with congenital heart disease and an implantable cardioverter defibrillator.
    Coutinho Cruz M; Viveiros Monteiro A; Portugal G; Laranjo S; Lousinha A; Valente B; Osório P; Silva Cunha P; de Sousa L; Oliveira JA; Agapito A; Martins Oliveira M; Pinto F; Cruz Ferreira R
    Congenit Heart Dis; 2019 Jul; 14(4):525-533. PubMed ID: 30889316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
    Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients.
    Zhang Y; Guallar E; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Tjong FV; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Tomaselli GF; Cheng A
    Heart Rhythm; 2015 Feb; 12(2):360-6. PubMed ID: 25446153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.
    Gold MR; Lambiase PD; El-Chami MF; Knops RE; Aasbo JD; Bongiorni MG; Russo AM; Deharo JC; Burke MC; Dinerman J; Barr CS; Shaik N; Carter N; Stoltz T; Stein KM; Brisben AJ; Boersma LVA;
    Circulation; 2021 Jan; 143(1):7-17. PubMed ID: 33073614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
    Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.